**Background and Rationale**
The apolipoprotein E epsilon 4 (APOE4) allele represents the strongest genetic risk factor for late-onset Alzheimer's disease (AD), carried by approximately 25% of the population and conferring a 3-fold increased risk for heterozygotes and 8-15-fold increased risk for homozygotes. While traditional therapeutic approaches have focused on amyloid-beta (Aβ) and tau pathology as primary targets, emerging evidence suggests that APOE4-mediated cellular dysfunction may pre
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.40
Evidence
0.46
Novelty
0.70
Feasibility
0.40
Impact
0.00
Druggability
0.50
Safety
0.50
Competition
0.50
Data
0.40
Reproducible
0.30
Score Breakdown
Dimension
APOE4-Driven Astrocyte Senesce
Mechanistic
0.400
Evidence
0.460
Novelty
0.700
Feasibility
0.400
Impact
0.000
Druggability
0.500
Safety
0.500
Competition
0.500
Data
0.400
Reproducible
0.300
Evidence
APOE4-Driven Astrocyte Senescence as Primary Target
Contradicting Evidence
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy.PMID:23296339
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies.PMID:31367008